| Protocol | Description | USC Satellite Location |
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
|
0C-20-14
Trial Leaders:
Jorge Nieva
| Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) Phase II Platform trial
Treatment:
Immunotherapy
|
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
|
0C-22-11
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Study of BA3071 in Patients with Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
0C-22-20
Trial Leaders:
Diana Hanna
| A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
|
0C-22-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-7
Trial Leaders:
Jacob Thomas
| A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes.
Treatment:
Immunomodulator
|
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose
Treatment:
Immunotherapy
|
|
0C-23-10
Trial Leaders:
Jacob Thomas
| A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
Treatment:
Biological Response Modifier
|
|
0C-23-11
Trial Leaders:
Anthony El-Khoueiry
| Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
Treatment:
Genetic
Immunotherapy
| USC Koreatown
|
0C-23-15
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-17
Trial Leaders:
Jacob Thomas
| Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma
Treatment:
Biological Response Modifier
|
|
0C-23-21
Trial Leaders:
Heinz Josef Lenz
| PhII-227 / NCI 10486: Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-24
Trial Leaders:
Heinz Josef Lenz
| Phase I Study of Autologous CD8+ And CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown
|
0C-23-25
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
Treatment:
Other
|
|
0C-23-8
Trial Leaders:
Syma Iqbal
| A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown, USC Newport Beach Oncology
|
0S-20-8
Trial Leaders:
Gino In
| An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Treatment:
Other
Vaccine
|
|
1B-10-3
Trial Leaders:
Evanthia Roussos torres
| Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.
Treatment:
Chemotherapy: Systemic
|
|
1B-21-1
Trial Leaders:
Evanthia Roussos torres
| A Randomized, Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Estrogen Receptor Positive, HER2 Negative Breast Cancer (DARE)
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
1B-21-3
Trial Leaders:
Priya Jayachandran
| A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd
Treatment:
Other
| USC Newport Beach Oncology
|
1B-21-8
Trial Leaders:
Danielle Sterrenberg
| A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Treatment:
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
1B-22-2
Trial Leaders:
Fumito Ito
| A Phase I Study of In Situ Immunomodulation with CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC in Patients with Unresectable and Metastatic Solid Tumors with Injectable Palpable Disease
Treatment:
Immunotherapy
Radiation: External
|
|
1B-22-3
Trial Leaders:
Priya Jayachandran
| A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual Disease (EMPOWER)
Treatment:
Chemotherapy: Systemic
|
|
1B-23-3
Trial Leaders:
Daphne Stewart
| A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Treatment:
Chemotherapy: Systemic
| USC Koreatown, USC Newport Beach Oncology
|
1B-23-4
Trial Leaders:
Daphne Stewart
| A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
1B-23-5
Trial Leaders:
Daphne Stewart
| An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Participants Over 18 Years of Age with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
Treatment:
Biological Response Modifier
Other
|
|
2N-22-1
Trial Leaders:
Jorge Nieva
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
CTSU-A011801
Trial Leaders:
Priya Jayachandran
| The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Treatment:
Other
| USC Koreatown, USC Newport Beach Oncology
|
CTSU-A211801
Trial Leaders:
Darcy Spicer
| BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation
Treatment:
Immunotherapy
|
|
CTSU-CCTG MA.39
Trial Leaders:
Jason Ye
| A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Treatment:
Radiation: External
|
|
NRG-BR007
Trial Leaders:
Diane Ling
| A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Treatment:
Hormone
Radiation: External
|
|
NRG-BR008
Trial Leaders:
Jason Ye
| A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*)
Treatment:
(No treatments specified) |
|
| Protocol | Description | USC Satellite Location |
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
|
0C-18-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
|
0C-18-21
Trial Leaders:
Diana Hanna
| A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
|
0C-19-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer
Treatment:
Immunotherapy
|
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
| USC Newport Beach Oncology
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
|
0C-20-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
|
0C-20-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-20-24
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
|
0C-21-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-21-8
Trial Leaders:
Heinz Josef Lenz
| PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Treatment:
Other
|
|
0C-21-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Treatment:
Other
|
|
0C-22-11
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Study of BA3071 in Patients with Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-12
Trial Leaders:
Diana Hanna
| A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-15
Trial Leaders:
Jacob Thomas
| A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Treatment:
Immunotherapy
|
|
0C-22-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-17
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-Label, First-in-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-19
Trial Leaders:
Anthony El-Khoueiry
| First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease
Treatment:
Biological Response Modifier
|
|
0C-22-20
Trial Leaders:
Diana Hanna
| A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
|
0C-22-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose
Treatment:
Immunotherapy
|
|
0C-23-1
Trial Leaders:
Jacob Thomas
| An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Treatment:
Immunotherapy
Other
|
|
0C-23-10
Trial Leaders:
Jacob Thomas
| A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
Treatment:
Biological Response Modifier
|
|
0C-23-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-14
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
Other
|
|
0C-23-15
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-17
Trial Leaders:
Jacob Thomas
| Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma
Treatment:
Biological Response Modifier
|
|
0C-23-18
Trial Leaders:
Anthony El-Khoueiry
| A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-24
Trial Leaders:
Heinz Josef Lenz
| Phase I Study of Autologous CD8+ And CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown
|
0C-23-25
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-26
Trial Leaders:
Jacob Thomas
| A Phase 1 Study of NM32-2668 (Anti-ROR1 / Anti-CD3/ Anti-HSA Tri- Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0C-23-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
|
0C-23-5
Trial Leaders:
Anthony El-Khoueiry
| A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
Treatment:
Chemotherapy: Local
|
|
0C-23-6
Trial Leaders:
Jacob Thomas
| Phase 1 Clinical Study on the Tolerability of Utidelone Capsules in Patients with Advanced Solid Tumors
Treatment:
Other
|
|
0C-23-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
Treatment:
Other
|
|
0C-23-8
Trial Leaders:
Syma Iqbal
| A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors
Treatment:
Autologous Bone Marrow Transplant
| USC Koreatown, USC Newport Beach Oncology
|
0C-23-9
Trial Leaders:
Jacob Thomas
| Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
|
0S-23-3
Trial Leaders:
Robert Hsu
| PhI-138 / NCI 10509: A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
Treatment:
Biological Response Modifier
Immunotherapy
| USC Koreatown, USC Newport Beach Oncology
|
| Protocol | Description | USC Satellite Location |
0S-04-7
Trial Leaders:
Michael Press
| USC Tumor and Tissue Bank.
|
|
0S-11-5
Trial Leaders:
Amir Goldkorn
| Circulating Tumor Cell Collection from Cancer Patients.
|
|
0S-12-4
Trial Leaders:
Charite Ricker
| USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.
|
|
0S-15-12
Trial Leaders:
Bodour Salhia
| Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.
|
|
0S-15-16
Trial Leaders:
Casey O'Connell
| Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls
|
|
0S-20-10
Trial Leaders:
Kimberly Miller
| Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study
|
|
0S-22-7
Trial Leaders:
Fumito Ito
| Novel Circulating Markers for Monitoring Response to Anti-Cancer Therapy
|
|
1B-11-1
Trial Leaders:
Evanthia Roussos torres
| Breast Cancer Blood Biorepository.
| USC Newport Beach Oncology
|
1B-13-2
Trial Leaders:
Evanthia Torres
| Core Biopsies of Breast Tumor Tissue Repository.
|
|
1B-19-5
Trial Leaders:
Bino Varghese
| Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics
|
|
1B-21-6
Trial Leaders:
Bodour Salhia
| A Comprehensive Breast Cancer Survivorship Biorepository
|
|
1B-22-1
Trial Leaders:
Peter Conti
| Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
|
|
3G-07-3
Trial Leaders:
Heinz Josef Lenz
| Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.
|
|
6CNS-07-1
Trial Leaders:
Thomas Chen
| Establishment of USC CNS and Spine Tumor Bank.
|
|
CTSU-EA1151
Trial Leaders:
Linda Hovanessian
| Comparison of Tomosynthesis to Digital Mammography in Breast Cancer Screening
|
|
CTSU-EA1211
Trial Leaders:
Peter Conti
| Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
|
|
SWOG-S2013
Trial Leaders:
Varsha Tulpule
| Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
|
|
